Descovy (emtricitabine / tenofovir alafenamide) is a prescription antiretroviral pill used to treat and prevent human immunodeficiency virus (HIV) infection. It's FDA approved for use with other HIV medications to treat HIV in adults and children. It's also approved for pre-exposure prophylaxis (PrEP) to help reduce the risk of getting HIV in adults and teens. You take it once a day by mouth, with or without food. Some common side effects include nausea and diarrhea.
Descovy (emtricitabine / tenofovir alafenamide) is a combination of two HIV antiretroviral medications: emtricitabine and tenofovir alafenamide.
Both medications are nucleoside reverse transcriptase inhibitors (NRTIs). They work by blocking an enzyme (protein) called reverse transcriptase, which HIV uses to make copies of itself. By stopping this process, Descovy (emtricitabine / tenofovir alafenamide) helps prevent the virus from spreading in the body and reduces the risk of infection when used for PrEP.
Source: DailyMed
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report to your care team if they continue or are bothersome):
Not approved for PrEP in people at risk from vaginal sex
Common side effects are diarrhea and nausea
Requires regular lab tests
Take Descovy (emtricitabine / tenofovir alafenamide) every day to help prevent or treat HIV the best it can. Missing doses can make it easier for HIV to change and stop the medication from working.
You can take Descovy (emtricitabine / tenofovir alafenamide) with or without food.
Get your routine blood tests done on time while taking Descovy (emtricitabine / tenofovir alafenamide). These tests help your care team make sure the medication is working and not causing side effects.
Descovy (emtricitabine / tenofovir alafenamide) can interact with many medications. Tell your care team about everything you're taking — prescription, over-the-counter products, and supplements — before starting Descovy (emtricitabine / tenofovir alafenamide).
Taking Descovy (emtricitabine / tenofovir alafenamide) can sometimes affect your kidneys. It’s a good idea to avoid other medications that can cause kidney damage while you’re taking this medication.
If you're pregnant and taking Descovy (emtricitabine / tenofovir alafenamide), know there’s a pregnancy registry that tracks outcomes. Your care team can help you report this information to help others.
If you have HIV and are breastfeeding, Descovy (emtricitabine / tenofovir alafenamide) might increase risks for your baby. This includes passing HIV, drug resistance, or side effects. Talk to your prescriber about whether breastfeeding is safe.
More tips for HIV PrEP:
If you think you were exposed to HIV or have symptoms like fever, muscle pain, tiredness, or rash, tell your care team right away. Descovy (emtricitabine / tenofovir alafenamide) isn't a full treatment for HIV and shouldn’t be used alone if you’ve already been infected.
Taking Descovy (emtricitabine / tenofovir alafenamide) for HIV PrEP should be part of a full prevention plan. This includes taking your medication daily and practicing safer sex, like using condoms, to help lower the risk of sexually transmitted infections (STIs).
Make sure to get tested for HIV before starting PrEP and then at least every 3 months while taking it. If you get HIV while on Descovy (emtricitabine / tenofovir alafenamide), it can make the virus harder to treat, so routine testing is important.
Descovy (emtricitabine / tenofovir alafenamide) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Risk factors: Have hepatitis B and HIV | Stopping Descovy (emtricitabine / tenofovir alafenamide) | Severe liver problems
Before you start Descovy (emtricitabine / tenofovir alafenamide), your prescriber will test you for hepatitis B virus (HBV). If you already have hepatitis B, stopping Descovy (emtricitabine / tenofovir alafenamide) could suddenly make your liver condition worse (called an HBV flare-up). Don't stop taking the medication without talking with your prescriber first. Make sure to get your refills on time so you don't miss any doses. If you do need to stop taking the medication, your prescriber might continue to check your liver with blood tests for several months to watch for signs of an HBV flare-up.
Descovy (emtricitabine / tenofovir alafenamide) might not always fully prevent HIV infection, so it’s important to use other ways to protect yourself too. This includes practicing safer sex (like using condoms), knowing your partner’s HIV status, and getting tested at least every 3 months for HIV and other STIs. Taking Descovy (emtricitabine / tenofovir alafenamide) on time every day helps lower your chance of getting HIV.
Before starting Descovy (emtricitabine / tenofovir alafenamide), your prescriber might ask you about any recent situations where you could have been exposed to HIV — like unprotected sex or a recent STI. You'll also need to take an HIV test. Let your prescriber know if you have symptoms of HIV, such as fever, feeling tired, muscle pain, and skin rash, either before or during treatment.
Taking Descovy (emtricitabine / tenofovir alafenamide) can cause changes to your immune system known as immune reconstitution syndrome. This can happen when your immune system becomes more active after starting treatment and begins to fight infections it was too weak to handle before. You might notice signs of infections like tuberculosis (TB) or cytomegalovirus (CMV). In rare cases, your immune system might become so strong that it starts attacking healthy parts of your body, also known as an autoimmune response. These symptoms can show up even months after starting treatment. Always let your care team know if you notice new or unusual symptoms while taking your HIV medication.
Risk factors: History of kidney problems | Taking other medications known to harm kidneys
Some people who take Descovy (emtricitabine / tenofovir alafenamide) have had kidney problems. To help protect your kidneys, try to avoid other medications that can also harm the kidneys, like high doses of nonsteroidal anti-inflammatory drugs (NSAIDs). Before you start Descovy (emtricitabine / tenofovir alafenamide), and during treatment, your prescriber will check your kidney health with blood tests and urine tests. Let your prescriber know right away if you experience bone or muscle pain, pain in your arms or legs, and general weakness that doesn't go away. These might be signs of kidney problems.
In rare cases, Descovy (emtricitabine / tenofovir alafenamide) can cause a serious condition called lactic acidosis, which is when too much acid builds up in your blood. It can also cause severe liver problems which can sometimes be life-threatening.
Make sure to get blood tests done while you take Descovy (emtricitabine / tenofovir alafenamide) so your prescriber can check for these harmful side effects and make sure the medication is still safe to take. Tell your care team right away if you feel very weak or tired, have trouble breathing, nausea, vomiting, stomach pain, or notice your skin or eyes turning yellow.
HIV treatment
Adults and children who weigh at least 77 lbs: The typical dose is one tablet (200 mg emtricitabine / 25 mg tenofovir alafenamide) by mouth once a day.
*Children who weigh less than 77 lbs
Weight 55 lbs to less than 77 lbs: The typical dose is one tablet (200 mg emtricitabine / 25 mg tenofovir alafenamide) by mouth once a day.
Weight 31 lbs to less than 55 lbs: The typical dose is one tablet (120 mg emtricitabine / 5 mg tenofovir alafenamide) by mouth once a day.
Prevention of HIV (PrEP)
Adults and teens who weigh at least 77 lbs: The typical dose is one tablet (200 mg emtricitabine / 25 mg tenofovir alafenamide) by mouth once a day.
Have a positive or unknown HIV status (for PrEP only)
Treatment of HIV infection
Prevention of HIV infection (PrEP or pre-exposure prophylaxis)
By providing your email, you consent to receive marketing communications from GoodRx, which may include content and/or data related to men’s health, women's health, reproductive care, or sexual health. You agree to the GoodRx Terms of Use and acknowledge the Privacy Policy. You can unsubscribe at any time.
Centers for Disease Control and Prevention. (2025). What is PrEP.
Clinical Info HIV.gov. (nd). Reverse Transcriptase (RT).
Clinical Info HIV.gov. (2024). Initial combination antiretroviral regimens for people with HIV.
Gilead Sciences, Inc. (2025). Descovy- emtricitabine and tenofovir alafenamide tablet [package insert]. DailyMed.
HIV.gov (2024). Taking Your HIV Medicine as Prescribed.
Lake, J. E., et al. (2021). Impact of Integrase inhibitors and tenofovir alafenamide on weight gain in people with HIV. Current Opinion in HIV and AIDS.
National Institute of Allergy and Infectious Diseases. (2025). 10 things to know about HIV suppression.
US Public Health Service. (2021). Preexposure prophylaxis for the prevention of HIV infection in the United States.
Thapa, S., et al. (2023). Immune reconstitution inflammatory syndrome. StatPearls.
The Antiretroviral Pregnancy Registry. (2025). Information for Patients.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.